Advocating for Demonstration of Disease Modification-Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly?

JAMA Neurol. 2023 Jul 1;80(7):659-660. doi: 10.1001/jamaneurol.2023.0815.
No abstract available

Plain language summary

This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Biomarkers
  • Clinical Trials as Topic
  • Humans
  • Research Design


  • Biomarkers